PAQR9 and metabolic dysfunction-associated steatotic liver disease: These responses indicated that BLNC1 may work cooperatively with LXR to control hepatic lipid metabolism, which may serve as a therapeutic target for the treatment of NAFLD patients (Zhao et al., 2018).